Compare CarMax, Inc (KMX) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs Mesoblast Limited — how do they compare? CarMax, Inc trades at $52.72 (market cap $7.64B), while Mesoblast Limited trades at $14.24 (market cap $1.75B). The key difference: CarMax, Inc is far larger — about 4.4× Mesoblast Limited's market cap, and CarMax, Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold CarMax, Inc for 49 Days and Mesoblast Limited for 15 Days on average.
| KMX | MESO | |
|---|---|---|
Market Cap | $7.64B | $1.75B |
Volume | 3,610,116 | 239,027 |
Sector | Consumer Cyclical | Health |
52-Week High | $64.22 | $20.96 |
52-Week Low | $30.88 | $13.19 |
Typical Hold Time | 49 Days | 15 Days |
Enterprise Value | $25.34B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $52.82, down 0.86% today, with a bearish technical signal despite recent earnings beats. The company reported strong Q2 2026 results with EPS of $1.16 beating estimates by 58%, driven by 19.5% revenue growth to $7.9 billion. Valuation metrics show a P/E of 25.37 and P/S of 0.28, while profitability remains modest with 1.06% net margin. Recent news highlights the company's 'Shift into GEAR' turnaround strategy showing early success.
KMX presents a mixed outlook with improving operational performance offset by high debt levels and competitive pressures. The consensus price target of $58.89 suggests 11% upside potential, but analysts remain cautious with 62% hold ratings. Key risks include cyclical auto market exposure and interest rate sensitivity, while catalysts include continued execution of the turnaround strategy and potential share buybacks.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
